• Something wrong with this record ?

Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines

A. Balkrishna, V. Arya, A. Rohela, A. Kumar, R. Verma, D. Kumar, E. Nepovimova, K. Kuca, N. Thakur, N. Thakur, P. Kumar

. 2021 ; 9 (10) : . [pub] 20211004

Language English Country Switzerland

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc22001628

Grant support
Excellence project UHK CEP Register
Excellence Project PrF UHK CEP Register

SARS-CoV-2 claimed numerous lives and put nations on high alert. The lack of antiviral medications and the small number of approved vaccines, as well as the recurrence of adverse effects, necessitates the development of novel treatment ways to combat COVID-19. In this context, using databases such as PubMed, Google Scholar, and Science Direct, we gathered information about nanotechnology's involvement in the prevention, diagnosis and virus-like particle vaccine development. This review revealed that various nanomaterials like gold, polymeric, graphene and poly amino ester with carboxyl group coated magnetic nanoparticles have been explored for the fast detection of SARS-CoV-2. Personal protective equipment fabricated with nanoparticles, such as gloves, masks, clothes, surfactants, and Ag, TiO2 based disinfectants played an essential role in halting COVID-19 transmission. Nanoparticles are used not only in vaccine delivery, such as lipid nanoparticles mediated transport of mRNA-based Pfizer and Moderna vaccines, but also in the development of vaccine as the virus-like particles elicit an immune response. There are now 18 virus-like particle vaccines in pre-clinical development, with one of them, developed by Novavax, reported being in phase 3 trials. Due to the probability of upcoming COVID-19 waves, and the rise of new diseases, the future relevance of virus-like particles is imperative. Furthermore, psychosocial variables linked to vaccine reluctance constitute a critical problem that must be addressed immediately to avert pandemic.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22001628
003      
CZ-PrNML
005      
20220112153646.0
007      
ta
008      
220107s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/vaccines9101129 $2 doi
035    __
$a (PubMed)34696237
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Balkrishna, Acharya $u Patanjali Herbal Research Department, Patanjali Research Institute, Haridwar 249405, India $u Department of Allied Sciences, University of Patanjali, Haridwar 249405, India
245    10
$a Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines / $c A. Balkrishna, V. Arya, A. Rohela, A. Kumar, R. Verma, D. Kumar, E. Nepovimova, K. Kuca, N. Thakur, N. Thakur, P. Kumar
520    9_
$a SARS-CoV-2 claimed numerous lives and put nations on high alert. The lack of antiviral medications and the small number of approved vaccines, as well as the recurrence of adverse effects, necessitates the development of novel treatment ways to combat COVID-19. In this context, using databases such as PubMed, Google Scholar, and Science Direct, we gathered information about nanotechnology's involvement in the prevention, diagnosis and virus-like particle vaccine development. This review revealed that various nanomaterials like gold, polymeric, graphene and poly amino ester with carboxyl group coated magnetic nanoparticles have been explored for the fast detection of SARS-CoV-2. Personal protective equipment fabricated with nanoparticles, such as gloves, masks, clothes, surfactants, and Ag, TiO2 based disinfectants played an essential role in halting COVID-19 transmission. Nanoparticles are used not only in vaccine delivery, such as lipid nanoparticles mediated transport of mRNA-based Pfizer and Moderna vaccines, but also in the development of vaccine as the virus-like particles elicit an immune response. There are now 18 virus-like particle vaccines in pre-clinical development, with one of them, developed by Novavax, reported being in phase 3 trials. Due to the probability of upcoming COVID-19 waves, and the rise of new diseases, the future relevance of virus-like particles is imperative. Furthermore, psychosocial variables linked to vaccine reluctance constitute a critical problem that must be addressed immediately to avert pandemic.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Arya, Vedpriya $u Patanjali Herbal Research Department, Patanjali Research Institute, Haridwar 249405, India $u Department of Allied Sciences, University of Patanjali, Haridwar 249405, India
700    1_
$a Rohela, Akansha $u Patanjali Herbal Research Department, Patanjali Research Institute, Haridwar 249405, India
700    1_
$a Kumar, Ashwani $u Patanjali Herbal Research Department, Patanjali Research Institute, Haridwar 249405, India
700    1_
$a Verma, Rachna $u School of Biological and Environmental Sciences, Shoolini University of Biotechnology and Management Sciences, Solan 173229, India
700    1_
$a Kumar, Dinesh $u School of Bioengineering and Food Technology, Shoolini University of Biotechnology and Management Sciences, Solan 173229, India
700    1_
$a Nepovimova, Eugenie $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, 50003 Hradec Kralove, Czech Republic
700    1_
$a Kuca, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, 50003 Hradec Kralove, Czech Republic $u Biomedical Research Center, University Hospital in Hradec Kralove, Sokolska 581, 50005 Hradec Kralove, Czech Republic
700    1_
$a Thakur, Naveen $u Department of Physics, Career Point University, Hamirpur 177001, India
700    1_
$a Thakur, Nikesh $u Department of Physics, Career Point University, Hamirpur 177001, India
700    1_
$a Kumar, Pankaj $u Department of Physics, Career Point University, Hamirpur 177001, India
773    0_
$w MED00200686 $t Vaccines $x 2076-393X $g Roč. 9, č. 10 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34696237 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220107 $b ABA008
991    __
$a 20220112153642 $b ABA008
999    __
$a ind $b bmc $g 1745548 $s 1152775
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 9 $c 10 $e 20211004 $i 2076-393X $m Vaccines $n Vaccines (Basel) $x MED00200686
GRA    __
$a Excellence project $p UHK
GRA    __
$a Excellence Project PrF $p UHK
LZP    __
$a Pubmed-20220107

Find record

Citation metrics

Archiving options